- Home
- UHT vs UPB Comparison
UHT vs UPB Comparison
Compare UHT & UPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UHT
- UPB
- Stock Information
- Founded
- UHT 1986
- UPB 2021
- Country
- UHT United States
- UPB United States
- Employees
- UHT N/A
- UPB N/A
- Industry
- UHT Real Estate Investment Trusts
- UPB
- Sector
- UHT Real Estate
- UPB
- Exchange
- UHT Nasdaq
- UPB NYSE
- Market Cap
- UHT 566.7M
- UPB 521.3M
- IPO Year
- UHT N/A
- UPB 2024
- Fundamental
- Price
- UHT $38.56
- UPB $15.19
- Analyst Decision
- UHT
- UPB Strong Buy
- Analyst Count
- UHT 0
- UPB 4
- Target Price
- UHT N/A
- UPB $56.50
- AVG Volume (30 Days)
- UHT 56.3K
- UPB 411.9K
- Earning Date
- UHT 07-28-2025
- UPB 08-14-2025
- Dividend Yield
- UHT 7.63%
- UPB N/A
- EPS Growth
- UHT N/A
- UPB N/A
- EPS
- UHT 1.30
- UPB N/A
- Revenue
- UHT $99,952,000.00
- UPB $2,296,000.00
- Revenue This Year
- UHT $3.87
- UPB N/A
- Revenue Next Year
- UHT $3.97
- UPB N/A
- P/E Ratio
- UHT $30.95
- UPB N/A
- Revenue Growth
- UHT 0.31
- UPB N/A
- 52 Week Low
- UHT $34.56
- UPB $5.14
- 52 Week High
- UHT $47.30
- UPB $29.46
- Technical
- Relative Strength Index (RSI)
- UHT 33.23
- UPB N/A
- Support Level
- UHT $40.24
- UPB N/A
- Resistance Level
- UHT $41.99
- UPB N/A
- Average True Range (ATR)
- UHT 0.88
- UPB 0.00
- MACD
- UHT -0.23
- UPB 0.00
- Stochastic Oscillator
- UHT 2.00
- UPB 0.00
About UHT Universal Health Realty Income Trust
Universal Health Realty Income Trust is a healthcare REIT. The company is engaged in the business of investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. The company actively manages a portfolio of healthcare and human service facilities. The revenue and net income are generated from the operation of the investment portfolio, located throughout the United States.
About UPB UPSTREAM BIO INC
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.